Chronic hepatitis B (CHB) is treated with nucleos(t)ide analogues (NAs). The reverse transcriptase (RT) region in the hepatitis B virus (HBV) genome mutates to resist NA treatment, yet the RT mutations have not been well characterized. Furthermore, the HBV genotype might influence RT sequence evolution, NA resistance (NAr) mutation patterns and drug resistance development. We examined 42 NAr mutation sites in 169 untreated and 131 NA-treated CHB patient samples. Patients were identified with HBV-B and HBV-C genotype infections, with a higher prevalence and mutation frequency of HBV-C than HBV-B. Seventeen reported NAr mutation sites and 13 novel mutations were detected. NAr-related mutation prevalence was significantly higher in NA-treated versus untreated patients. Primary antiviral-resistant mutants only existed in NA-treated patients. Sequencing data revealed seven HBV-C-specific mutations and three HBV-B-specific mutations. In conclusion, NA treatment and HBV genotype might constitute the selection basis and promote NA-resistant HBV strain evolution under antiviral therapy.
Chronic hepatitis B (CHB), a life-threatening liver disease, is a global public health concern, caused by hepatitis B virus (HBV) (Chen et al., 2012; Franco et al., 2012; Zhao et al., 2010) . IFN and nucleos(t)ide analogue (NAs) CHB treatments have been approved in China, including lamivudine (LAM), adefovir dipivoxil (ADV), entecavir and telbivudine (Pan et al., 2013; Shaw et al., 2006) . NA treatment is more convenient than IFN-based therapy, has fewer side effects and more quickly reduces HBV DNA levels. NA therapy inhibits HBV DNA polymerase activity and DNA replication by targeting HBV-encoded reverse transcriptase (RT) (Leung et al., 2001; Locarnini & Mason, 2006; Locarnini et al., 2004) . However, NA therapy is challenged by several conditions: viral persistence in infected hepatocytes, limited NA availability and antiviral NA resistance (NAr) mutations during long-term NA treatment (Fung et al., 2011; Liaw et al., 2004; Locarnini & Mason, 2006) , which are the most important factors responsible for treatment failure (Locarnini, 2008; Lok et al., 2007b) . Therefore, it is important to understand the mechanism underlying drug-resistant mutation evolution to prevent and control drug resistance (Khudyakov, 2010) .
A previous study analysed amino acid substitutions at 42 potential NAr mutation sites in the HBV full-length RT sequence (Baldick et al., 2008; Bartholomeusz et al., 2004; Ghany & Doo, 2009; Keeffe et al., 2008; Liu et al., 2010) . NAr-associated mutations within the HBV RT region can be classified into five categories : primary drug-resistant mutations (category 1), compensatory mutations (category 2), putative NAr mutations (category 3), pre-treatment mutations (category 4) and new mutations (category 5) (Table S1 , available in the online Supplementary Material).
Recent studies demonstrated that the HBV genotype contributes to drug-resistant mutant evolution and selection . Moreover, HBV genotypes differ in LAM-resistant mutation patterns, as HBV-A favours the rtM204V mutation, whilst HBV-B-D prefer rtM204I (Mirandola et al., 2012) . In addition, the rtL180M mutation is significantly associated with the rtM204V mutation in HBV-A-C (Damerow et al., 2010) .
A better understanding of the NAr-associated mutations would improve clinical outcomes and elucidate the drug resistance mechanism. Therefore, this study aimed to compare mutations present in NA-treated and untreated CHB samples, and to relate HBV genotype to NAr mutation evolution and patterns. Sera were obtained from 169 untreated and 131 NA-treated CHB patients recruited from southern China between April 2008 and July 2009. The study protocol was approved by the Ethics Committee of the Shanghai Jiao Tong University School of Medicine and informed consent was obtained from each patient. HBV DNA was extracted from 200 ml patient serum using a QIAamp DNA Blood kit (Qiagen). Semi-nested PCR was used to amplify the HBV full-length RT region and PCR product-based direct sequencing was performed as described previously . Samples were genotyped using the Viral Genotyping Tool (National Center for Biotechnology Information) and phylogeny was analysed with MEGA 4.0 software. Fortytwo potential NAr mutation sites in the HBV RT region (Table S1 ) were examined for amino acid mutations. Nucleotide sequences were analysed using Chromas and DNAMAN 8 software. Quantitative values and qualitative values were evaluated by Student's t-test and the x 2 test, respectively, with SPSS 11.0 software where appropriate. All P values were two-tailed. P,0.05 was considered statistically significant.
The majority of patients were male, hepatitis Be antigen (HBeAg)-positive and infected with HBV-B (76.7 %, 230/ 300), whereas the remainder (23.3 %, 70/300) were infected with HBV-C (Table S2 ). In agreement with previous studies, this study demonstrated that HBV-B is the most represented genotype in southern China (Zhang et al., 2011) . No significant differences were observed for gender or the HBV-B/C ratio between the NA-treated and untreated groups. However, the untreated patients were older, and had higher serum HBV DNA levels and HBeAgpositive rates, than those in the NA-treated group. An analysis of mutation distribution amongst genotypes showed significantly higher HBV-C (70.0 %) mutation prevalence compared with HBV-B (46.1 %). Moreover, HBV-C mutation frequency (7.0 %) was higher than that for HBV-B (3.1 %) (Table S3 ).
Single or multiple RT region mutations were detected in 155 patients (155/300, 51.7 %; Table S4 ). Overall, serum HBV DNA levels were significantly lower in patients with viral DNA with multiple mutations compared with DNA without mutations or with a single mutation (P,0.001). Similar results were found in HBV-B and -C patients; the viral load of the group without mutations was significantly higher than that of the multiple-mutations group (B, P50.03; C, P,0.001). Moreover, the HBeAg-positive rate was higher in the absence of mutations (93.1 %) compared with a single substitution (64.9 %, P,0.001) or with multiple mutations (49.3 %, P,0.001). In addition, HBV-C patients usually carried multiple mutations. Notably, patients administered LAM and ADV sequential therapy harboured significantly more viral DNA with multiple mutations than with a single mutation or no mutations (Table 1) .
Amino acid sequences encoded by the HBV polymerase RT region from 300 CHB patient samples were aligned and compared with the corresponding genotype reference amino acid sequences. We identified 28 amino acid mutation sites; 17 sites were amongst the 42 positions previously reported by Liu et al. (2010) (Table S1 ; the remaining 25 reported sites were not observed) and 11 sites were novel mutation sites. Amongst the 28 amino acid mutation sites, there were nine amino acid substitutions in seven resistance-associated positions (rtL80V, rtA181T/V, rtA194T, rtM204I/V, rtN236T, rtV173L and rtL180M; categories 1 and 2), 11 amino acid substitutions in 10 positions, which have been reported as potential NAr mutation sites (rtV191I, rtA200V, rtV207I, rtS213T, rtV214A, rtF221Y, rtL229V/W, rtP237H, rtN238T and rtR242S; categories 3 and 4) and 11 novel amino acid mutation sites (rtI187V, rtL199V, rtA211S, rtK212R, rtL220I/V, rtA222S, rtT225S, rtN226H, rtL228I, rtL235I and rtT240I; category 5). Amongst the known sites, 10 novel substitutions were identified (rtA194S, rtL80I, rtV207L/M, rtV214E, rtY221H/S, rtL229F/M and rtR242S). 
W 5.6 237 P P P P P H 6.2 Mutation sites at rtL80V, rtA194T/S, rtA200V, rtV207L/M, rtY221H/S, rtL229M, rtA211S, rtK212R, rtL220I/V, rtA222S, rtT225S, rtL228I, rtL235I and rtT240I were only present in HBV-B, whereas mutation sites at rtV173L, rtV191I, rtA200S, rtV207I, rtV214A, rtF221Y, rtP237H, rtN238T, rtR242S and rtL199V were found in HBV-C. Notably, the prevalence of mutations rtL80V, rtI187V and rtN226H in HBV-B was significantly higher than in HBV-C, whilst mutations rtL180M, rtV191I, rtA200S, rtV207I, rtF221Y, rtN238T and rtR242S were detected more frequently in HBV-C than HBV-B ( Table 2 ).
The classical category 1 and 2 NAr mutations were found in 93 NA-treated patients. Significant differences were found in the mutation prevalence of rtL80V, rtA181V/T, rtA194T/S, rtM204V/I, rtN236T, rtV173L and rtL180M between the untreated and NA-treated patients. A mutation at ADV resistance-associated sites rtA194T/S was found in two ADV-treated cases and an additional type S mutation was found at this site. No entecavir resistanceassociated mutations were found.
Some category 3 and 4 mutations showed significantly higher frequency in the NA-treated group than that in the untreated group (e.g. rtV191, rtV207, rtS213, rtV214, rtL229, rtP237, rtN238 and rtR242).
All new mutation sites found in this study were detected in NA-treated patients, and mutations rtI187V and rtN226H were also identified in untreated patients (Table S4 ).
The substitution prevalence in 28 amino acid mutation sites in the HBV RT region was determined for 169 untreated and 131 patients treated with four kinds of NA treatments (Table 3 ). There were only six sites with seven amino acid substitutions observed in the untreated group and no category 1 or 2 mutations were identified in untreated patient samples. However, for LAM monotherapy, ADV mono-therapy, LAM and ADV sequential therapy, and LAM combined with ADV therapy, we observed amino acid substitutions at 12, 20, 14 and six sites, respectively.
For category 1 and 2 mutations, five mutation types at four positions (rtL80V, rtV173L, rtL180M and rtM204V/I) were significantly associated with LAM therapy; rtA181T/V and rtN236T were the dominant mutations related to ADV therapy; rtL80V, rtV173L, rtL180M and rtM204V/I were dominant in LAM-containing treatment groups; and mutations rtA181T/V and rtN236T were observed in ADV-containing treatment groups. Moreover, rtA181V and rtN236T were restricted to the ADV mono-therapy group. Mutations rtM204V/I were the primary LAM 
Drug-resistant mutations in hepatitis B viral genomes resistance mutations, with 51.9 % (68/131) prevalence in the NA-treated group, and they were observed most frequently amongst all identified mutations. Mutation rtL180M was found in 35 patients with LAM as an initial treatment, and 22 and 13 patients were infected with HBV-C and -B, respectively. Moreover, 28 out of 35 patients with rtL180M also harboured rtM204V. Meanwhile, 29 patients carrying rtL80V were all infected with HBV-B and harboured rtM204I, and rtM204I was the dominant mutation in the patients receiving LAM and ADV sequential therapy and LAM combined with ADV therapy. Notably, in the LAM-containing treatment groups, rtL180M and rtM204I mutation prevalence in LAM and ADV sequential and combined therapy was significantly higher than in the LAM mono-therapy group. Furthermore, only LAMresistant mutations were found in LAM and ADV sequential therapy groups, whereas LAM-resistant and ADV-resistant mutations were identified for LAM combined with ADV therapy.
For category 3 and 4 mutations, the prevalence of four mutations (rtV191I, rtS213T, rtV214A and rtF221Y) was significantly higher in the ADV mono-therapy group versus the untreated group, LAM mono-therapy or combination therapy. Interestingly, rtV191I only existed in the ADV mono-therapy group and in HBV-C infections. rtL229 was significantly associated with LAM therapy; 13 out of 14 rtL229 sites were identified in LAM-containing therapy groups along with the LAM-resistant mutation rtM204V/I.
Regarding new mutations, two mutations (rtI187V and rtN226H) had significantly higher prevalence than other new mutations. Additionally, rtI187V prevalence was not different amongst the five groups, whilst rtN226H prevalence was significantly higher in the LAM combined with ADV group. The other new mutations were primarily found in the ADV mono-therapy group. CHB patients present HBV genomes with antiviral resistance mutations in the RT region. The differences in these mutations between untreated and NA-treated CHB patients have not been well characterized. Therefore, we analysed HBV RT sequences from untreated and NAtreated patients to understand molecular evolution and drug-resistant HBV strain development during antiviral therapy. We found that 71.0 % (93/131) of HBV isolates from NA-treated patients harboured classical category 1 and 2 NAr mutations, whilst no classical mutations were found in untreated patients. Furthermore, the prevalence of putative category 3 and 4 NAr mutations in the NAtreated group was significantly higher than in the untreated group. These results suggested that genotype testing to monitor drug resistance is important for patients undergoing NA treatment. Meanwhile, the results also suggested that NA treatment is the major selecting factor of primary drug-resistant mutations and that NA treatment promotes putative NAr mutations (Li et al., 2012) . Moreover, several previous studies showed that primary NAr mutations occur in patients with no history of NA treatment (Han et al., 2009; Kobashi et al., 2009; Pastor et al., 2009) . Recently, another paper also reported that HBV resistance mutations were identified in 5 % of treatment-naïve patients by using INNO-LiPA (Fujirebio) line probe analysis (Mirandola et al., 2011) . However, we did not detect category 1 and 2 mutations in untreated patients. This discrepancy might be due to different detection methods, as we used direct sequencing, which might have a lower detection sensitivity than INNO-LiPA line probe analysis. Overall, the NA-treated group had a significantly higher mutation rate than the untreated group (NA-treated versus untreated: 99/131, 75.6 %; 9/169, 5.3 %; P,0.001).
In agreement with previous studies Locarnini, 2008; Locarnini & Mason, 2006; Lok et al., 2007a; Yang et al., 2010) , the prevalence of six classical NAr mutation sites (rtL80V, rtM204V/I, rtL180M, rtV173L, rtA181T and rtN236T) in the NA-treated group was significantly higher than in the untreated group (P,0.0001). Mutations at rtL80V, rtL180M, rtV173L and rtM204V/I were only identified in patients with LAMcontaining treatment, whilst mutations at rtA181T and rtN236T were only identified in patients with ADVcontaining treatment.
HBV genotypes may influence HBV evolution during antiviral treatment (Mirandola et al., 2012) . Svicher et al. (2009) reported that HBV-A and -D have different preferences for different LAM resistance mutation clusters, showing an important role of HBV genotypes in driving RT evolution under LAM treatment. Similarly, Liu et al. (2010) suggested that the HBV genetic background might contribute to drug-resistant mutations. The rtM204I and rtM204V prevalence is reportedly significantly different between HBV-B and -C (Pan et al., 2007) . However, no significant difference was observed in this study. Notably, previous studies showed that HBV genotypes correlated with drug-resistant mutation patterns (Mirandola et al., 2012; Seifer et al., 2009; Svicher et al., 2009) . Also, a recent study by Damerow et al. (2010) demonstrated that HBV genotypes differed in their LAM-resistant mutation pattern. In this study, we also found that some HBV NAr-related mutations have preferences for HBV genotypes. For example, rtL180M was mainly found in HBV-C, whilst rtL80V was only identified in HBV-B. Moreover, complementary mutations were observed; specifically, 100.0 % of rtL80V mutations occurred with rtM204I and 80.0 % of rtL180M mutations occurred with rtM204V, which is consistent with previous reports that rtL80V and rtL180M compensate for replication capacity, particularly for rtM204I and rtM204V, respectively (Lee et al., 2012; Warner et al., 2007) . Additionally, sequence analyses showed that HBV-C displayed higher mutation frequency and number of viral genomes with mutations than HBV-B. Thus, these results support the conclusions of previous reports that HBV genotypes influence disease severity and CHB prognosis (Kao et al., 2000; Maeshiro et al., 2007; Nakayoshi et al., 2003) .
In LAM and ADV combined therapy, only LAM resistancerelated mutations and no ADV-resistant mutations (rtA181T/ V and rtN236T) were identified. However, in LAM and ADV sequential therapy, we detected LAM resistance-related mutations and found two patients carrying ADV-resistant mutant rtA181T. This result is consistent with earlier findings that more varied ADV-resistant patterns were detected in patients receiving LAM and ADV sequential therapy than combined therapy (Liu et al., 2011; Rapti et al., 2007) . Taken together, these findings indicate that LAM and ADV sequential therapy may increase selection of ADV-resistant mutations. This situation likely occurs because LAM effectively suppresses ADV-resistant mutations, whilst ADV weakly suppresses LAM-resistant mutations. Furthermore, patients were more likely to have multiple mutations than have no mutation or a single mutation on LAM and ADV sequential therapy -a result consistent with a previous report showing that multidrug-resistant strains develop with sequential drug administration (Liu et al., 2011) .
In summary, primary resistance and secondary compensatory mutations were detected, and putative antiviralresistant and pre-treatment mutations were found in NAtreated patients with HBV-B or -C infections. These results demonstrated that NA treatment is associated with selection of these mutations and drives changes at putative NAr mutation sites. The prevalence, mutation frequency and number of patients carrying multiple mutations in HBV-C were significantly higher than those in HBV-B, suggesting that HBV-C has higher genetic variability than HBV-B. We observed that HBV genotypes may have different preferences for specific mutations and mutation patterns. The results provide new information on the role of NA treatment and HBV genotype in NAr HBV strain evolution and selection under antiviral therapy. The clinical implications of putative antiviral-resistant and pre-treatment mutations warrant further in vitro phenotypic assays to identify whether these mutations alone or in combination with primary resistance mutations might affect HBV drug susceptibility, replicative fitness and response to new antiviral drugs.
